Isoray’s Cesium-131 Spotlighted in Multiple Presentations at ASTRO
November 24 2020 - 8:13AM
The importance of Isoray, Inc.’s (NYSE American: ISR)
Cesium-131 in treating prostate and brain cancers was underscored
in multiple presentations at the ASTRO 2020 annual meeting in
Miami, Florida. During the virtual meeting, attendees were able to
learn about the increasing body of clinical evidence showing that
Cesium-131 has been found to be a valuable option in the treatment
of prostate and brain cancer for clinicians and their patients.
Commenting on the presentations, Isoray CEO Lori
Woods said, “It is very gratifying that so many Cesium-131 studies
made it through review to the meeting proceedings of the world’s
leading organization in radiation oncology. A tremendous amount of
work goes into each study at these respective institutions, and
each illustrates a continued interest in research related to
Cesium-131 cancer treatment. We are proud that our leading
brachytherapy treatment is at the forefront in bringing important
benefits to cancer patients and the medical professionals who care
for them.”
Two studies, The Effect of Positive Biopsy Cores on the
Prognosis of Patients with Intermediate Risk Prostate Cancer
Treated with Cs-131 Prostate Brachytherapy, Smith, Benoit, Beriwal,
et al. UPMC, Pittsburgh PA and Report of a Large Cohort of
Intermediate-Risk Prostate Cancer Patients Treated with Cs-131
Brachytherapy, Rodriguez-Lopez, Beriwal, Benoit, et al., UPMC
Pittsburgh PA, looked at the use of Cesium-131, commercially known
as Cesium Blu, in the treatment of intermediate risk prostate
cancer. These studies make the case that many intermediate risk
prostate cancer patients can be treated successfully with a
Cesium-131 implant alone. Importantly, these studies show the
excellent outcomes for Cesium-131 patients in this intermediate
risk patient group.
Among the presentations that looked at Cesium-131 in the
treatment of brain cancer was the study, A Matched Pair Analysis Of
Clinical Outcomes After Intracavitary Cesium-131 Brachytherapy
Versus Stereotactic Radiosurgery For Resected Brain Metastases,
Vanderbilt, Schwartz, et al., Weill Cornell Medical College, NY. In
this study, 30 patients with brain metastases underwent surgery and
Cesium-131 brachytherapy. These patients were “matched” to 60
patients who underwent treatment of brain metastases with surgery
and stereotactic radiosurgery (SRS). The patients who
underwent Cesium-131 implantation at surgery as opposed to those
who underwent SRS following surgery had lower rates of local
recurrence and complications such as radiation necrosis.
Another study, Cs-131 Intracavitary Brachytherapy as an Adjunct
to Maximal Safe Resection for Locally Recurrent High-Grade Glioma,
Patel, Chen, Dusenbery, et al., Univ Minnesota, Minneapolis,
involved the use of GammaTile, powered by Cesium-131 in the
treatment of ten patients with brain cancers including some
patients with glioblastoma multiforme (GBM). These patients had all
been treated with surgery, chemotherapy, and radiation and their
cancers had progressed. Nine of the ten patients had failed
second line (salvage) therapy as well. The study demonstrated that
treatment with Cs-131/GammaTile offers a way to provide therapeutic
levels of re-irradiation that begin at the time of surgical
placement of the GammaTiles. The successful delivery of high dose
radiation with a low rate of complications and no radiation
necrosis is very promising in the treatment of these brain
malignancies.
Isoray is a medical technology company and innovator in seed
brachytherapy. The Company is the world’s only producer of
Cesium-131 brachytherapy, commercially known as Cesium Blu, which
is powering expanding internal radiation treatment options
throughout the body for difficult to treat lung, brain,
gynecological, head and neck, pelvic, and colorectal cancers as
well as prostate cancer.
About IsorayIsoray, Inc., through its
subsidiary, Isoray Medical, Inc. is the sole producer of Cesium-131
brachytherapy seeds, which are expanding brachytherapy options
throughout the body. Learn more about this innovative Richland,
Washington company and explore the many benefits and uses of
Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray.
Follow us on Twitter @Isoray.
Safe Harbor StatementStatements in this news
release about Isoray’s future expectations, including whether the
studies discussed in this news release will have favorable outcomes
in commercial settings, the advantages of Cesium-131 and its
delivery systems coupled with surgery, the perception by patients
of quality of life outcomes compared to other treatment options,
whether demand for and use of Cesium-131 will increase or continue
as anticipated and all other statements in this release, other than
historical facts, are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995
(“PSLRA”). This statement is included for the express purpose
of availing Isoray, Inc. of the protections of the safe harbor
provisions of the PSLRA. It is important to note that actual
results and ultimate corporate actions could differ materially from
those in such forward-looking statements based on such factors as
whether additional studies are released that support the
conclusions of the studies discussed in this news release, whether
ongoing patient results are favorable and in line with the
conclusions of clinical studies and initial patient results,
physician acceptance, training and use of our products, whether we,
our distributors and our customers will successfully obtain and
maintain all required regulatory approvals and licenses to market,
sell and use our products in its various forms, changes in laws and
regulations applicable to our products, and other risks detailed
from time to time in Isoray’s reports filed with the U.S.
Securities Exchange Commission. Unless required to do so by
law, we undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact
Media and Public Relations: Sharon Schultz (302) 539-3747
Investor Relations: Mark Levin (501) 255-1910
IsoRay (AMEX:ISR)
Historical Stock Chart
From Mar 2024 to Apr 2024
IsoRay (AMEX:ISR)
Historical Stock Chart
From Apr 2023 to Apr 2024